Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | MGAM | O43451 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SI | P14410 | 1/20 | 0.31 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.31 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acrylic Acid SCHEMBL27441874 | 0.77 | LMNA (0.48) | LMNAALOX15HSD17B10TSHRALDH1A1 | |
| Acrylic Acid SCHEMBL27464498 | 0.76 | LMNA (0.46) | LMNAALOX15HSD17B10TSHRALDH1A1 | |
| SCHEMBL37216 | 0.75 | — | — | |
| Acrylic Acid SCHEMBL28676784 | 0.74 | LMNA (0.56) | LMNAALOX15HSD17B10TSHRALDH1A1 | |
| Acrylic Acid SCHEMBL2273825 | 0.74 | — | — | |
| Acrylic Acid SCHEMBL233721 | 0.74 | LMNA (0.56) | LMNAALOX15HSD17B10TSHRALDH1A1 | |
| Acrylic Acid SCHEMBL8391669 | 0.74 | LMNA (0.56) | LMNAALOX15HSD17B10TSHRALDH1A1 | |
| Acrylic Acid SCHEMBL6841685 | 0.74 | LMNA (0.56) | LMNAALOX15HSD17B10TSHRALDH1A1 | |
| Hypochlorous Acid SCHEMBL8893750 | 0.73 | — | — | |
| SCHEMBL7145721 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12173086-B2 | Alpha-v beta-6 integrin ligands and uses thereof | Arrowhead Pharmaceuticals, Inc. (US) | 2024-12-24 | — | — | US | disclosed |
| CN-117285626-A | Alpha v beta 6 integrin ligand and its application | 箭头药业股份有限公司 | 2023-12-26 | — | — | CN | disclosed |
| US-11840688-B2 | Compositions and methods for inhibiting gene expression of Hif2alpha | Arrowhead Pharmaceuticals, Inc. (US) | 2023-12-12 | — | — | US | disclosed |
| CN-109952376-B | Alpha v beta 6 integrin ligand and its application | 箭头药业股份有限公司 | 2023-09-05 | — | — | CN | disclosed |
| CN-114601845-A | Composition and method for inhibiting expression of Hif2alpha gene | 箭头药业股份有限公司 | 2022-06-10 | — | — | CN | disclosed |
| EP-3981780-A1 | ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF | Arrowhead Pharmaceuticals, Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20220024975-A1 | ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2022-01-27 | — | — | US | disclosed |
| EP-3030244-B1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD PHARMACEUTICALS INC (US) | 2021-04-21 | — | — | EP | disclosed |
| CN-109952376-A | α v β 6 integrin ligands and uses thereof | 箭头药业股份有限公司 | 2019-06-28 | — | — | CN | disclosed |
| CN-108064156-A | Compositions and methods for inhibiting expression of Hif2 α gene | 箭头药业股份有限公司 | 2018-05-22 | — | — | CN | disclosed |
| EP-3302516-A1 | BIOLOGICALLY CLEAVABLE TETRAPEPTIDE LINKING AGENTS | Arrowhead Pharmaceuticals, Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| EP-3302503-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF HIF2ALPHA | Arrowhead Pharmaceuticals, Inc. (US) | 2018-04-11 | — | — | EP | disclosed |
| CN-107614002-A | Biologically cleavable tetrapeptide linkers | 箭头药业股份有限公司 | 2018-01-19 | — | — | CN | disclosed |
| WO-2016196239-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF HIF2ALPHA | Arrowhead Pharmaceuticals, Inc. (US) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016196243-A1 | BIOLOGICALLY CLEAVABLE TETRAPEPTIDE LINKING AGENTS | Arrowhead Pharmaceuticals, Inc. (US) | 2016-12-08 | — | — | WO | disclosed |
| EP-3030244-A1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | Arrowhead Research Corporation (US) | 2016-06-15 | — | — | EP | disclosed |
| WO-2015021092-A1 | POLYCONJUGATES FOR DELIVERY OF RNAI TRIGGERS TO TUMOR CELLS IN VIVO | ARROWHEAD RESEARCH CORPORATION (US) | 2015-02-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024975-A1 | ALPHA-V BETA-6 INTEGRIN LIGANDS AND USES THEREOF | ITGAV, ITGA6, ITGB6 | LMNA 1470/4885ALOX15 4290/4885HSD17B10 4836/4885 |
| US-11840688-B2 | Compositions and methods for inhibiting gene expression of Hif2alpha | EPAS1, HIF1AN, EGLN2 | LMNA 1561/4885ALOX15 1852/4885HSD17B10 1424/4885 |
| US-12173086-B2 | Alpha-v beta-6 integrin ligands and uses thereof | ITGAV, ITGA6, ITGB6 | LMNA 1470/4885ALOX15 4290/4885HSD17B10 4836/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.